NAT1-IN-1 (compound 350) is a potent inhibitor targeting N-acetyltransferase 1 (NAT1), with an IC50 of 44 nM. It is applicable in the study of diseases characterized by metabolic hyperactivity, such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis.
Target:
Histone Acetyltransferase
* VAT and and shipping costs not included. Errors and price changes excepted
